COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab
COSMIC-313 is designed to answer an essential question of whether adding cabozantinib to dual checkpoint inhibition can improve outcomes, specifically in the untreated first-line poor- and intermediate-risk renal cell carcinoma patient population.
The COSMIC-313 study met its primary endpoint, demonstrating a significant progression-free survival benefit in patients receiving the triplet combination. In this MEDtalk, Toni Choueiri, Dana-Farber Cancer Institute, Boston, USA, gives his perspective on the results and the clinical impacts.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.